Zentalis Pharmaceuticals Doses First Patient In Phase 3 ASPENOVA Clinical Trial

Benzinga Newsdesk www.benzinga.com Positive 73.4%

Neg 0% Neu 0% Pos 73.4%

Global Phase 3, randomized, controlled trial comparing azenosertib to standard-of-care chemotherapy now enrolling
ASPENOVA designed as confirmatory study to support DENALI Phase 2 accelerated approval pathway, pending FDA feedback

Comments

No comments yet. Be the first!